Charles NJ, Boyer DF (2017) Mixed-phenotype acute leukemia: diagnostic criteria and pitfalls. Arch Pathol Lab Med 141:1462–1468. https://doi.org/10.5858/arpa.2017-0218-RA

Article  CAS  PubMed  Google Scholar 

Lao ZT, Ding LW, An O et al (2019) Mutational and transcriptomic profiling of acute leukemia of ambiguous lineage reveals obscure but clinically important lineage bias. Haematologica 104:e200–e203. https://doi.org/10.3324/haematol.2018.202911

Article  CAS  PubMed  PubMed Central  Google Scholar 

Takahashi K, Wang F, Morita K et al (2018) Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes. Nat Commun 9:2670. https://doi.org/10.1038/s41467-018-04924-z

Article  CAS  PubMed  PubMed Central  Google Scholar 

Qasrawi A, Ramlal R, Munker R et al (2020) Prognostic impact of Philadelphia chromosome in mixed phenotype acute leukemia (MPAL): a cancer registry analysis on real-world outcome. Am J Hematol 95:1015–1021. https://doi.org/10.1002/ajh.25873

Article  CAS  PubMed  Google Scholar 

Shimizu H, Yokohama A, Hatsumi N et al (2014) Philadelphia chromosome-positive mixed phenotype acute leukemia in the imatinib era. Eur J Haematol 93:297–301. https://doi.org/10.1111/ejh.12343

Article  CAS  PubMed  Google Scholar 

Wieduwilt MJ (2022) Ph+ ALL in 2022: is there an optimal approach? Hematology Am Soc Hematol Educ Program 2022:206–212. https://doi.org/10.1182/hematology.2022000338

Article  PubMed  PubMed Central  Google Scholar 

Martinelli G, Papayannidis C, Piciocchi A et al (2022) INCB84344-201: Ponatinib and steroids in frontline therapy for unfit patients with Ph+ acute lymphoblastic leukemia. Blood Adv 6:1742–1753. https://doi.org/10.1182/bloodadvances.2021004821

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kawajiri C, Tanaka H, Hashimoto S et al (2014) Successful treatment of Philadelphia chromosome-positive mixed phenotype acute leukemia by appropriate alternation of second-generation tyrosine kinase inhibitors according to BCR-ABL1 mutation status. Int J Hematol 99:513–518. https://doi.org/10.1007/s12185-014-1531-0

Article  CAS  PubMed  Google Scholar 

Takata H, Ikebe T, Sasaki H et al (2016) Two elderly patients with Philadelphia chromosome positive mixed phenotype acute leukemia who were successfully treated with dasatinib and prednisolone. Intern Med 55:1177–1181. https://doi.org/10.2169/internalmedicine.55.5223

Article  CAS  PubMed  Google Scholar 

Braun TP, Eide CA, Druker BJ (2020) Response and resistance to BCR-ABL1-targeted therapies. Cancer Cell 37:530–542. https://doi.org/10.1016/j.ccell.2020.03.006

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sasaki K, Jabbour EJ, Ravandi F et al (2016) Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a propensity score analysis. Cancer 122:3650–3656. https://doi.org/10.1002/cncr.30231

Article  CAS  PubMed  Google Scholar 

Cortes JE, Kantarjian H, Shah NP et al (2012) Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med 367:2075–2088. https://doi.org/10.1056/NEJMoa1205127

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cortes JE, Kim DW, Pinilla-Ibarz J et al (2013) A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 369:1783–1796. https://doi.org/10.1056/NEJMoa1306494

Article  CAS  PubMed  Google Scholar 

Foà R, Bassan R, Vitale A et al (2020) Dasatinib-Blinatumomab for Ph-positive acute lymphoblastic leukemia in adults. N Engl J Med 383:1613–1623. https://doi.org/10.1056/NEJMoa2016272

Article  PubMed  Google Scholar 

Jabbour E, Short NJ, Jain N et al (2023) Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial. Lancet Haematol 10:e24–e34. https://doi.org/10.1016/s2352-3026(22)00319-2

Article  CAS  PubMed  Google Scholar 

Wang H, Yang C, Shi T et al (2022) Venetoclax-ponatinib for T315I/compound-mutated Ph+ acute lymphoblastic leukemia. Blood Cancer J 12:20. https://doi.org/10.1038/s41408-022-00621-9

Article  PubMed  PubMed Central  Google Scholar 

Breccia M, Efficace F, Iurlo A et al (2018) Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: the possible role of ponatinib. Expert Opin Drug Saf 17:623–628. https://doi.org/10.1080/14740338.2018.1480719

Article  CAS  PubMed  Google Scholar 

Iurlo A, Cattaneo D, Malato A et al (2020) Low-dose ponatinib is a good option in chronic myeloid leukemia patients intolerant to previous TKIs. Am J Hematol 95:E260–E263. https://doi.org/10.1002/ajh.25908

Article  CAS  PubMed  Google Scholar 

Luciano L, Annunziata M, Attolico I et al (2020) The multi-tyrosine kinase inhibitor ponatinib for chronic myeloid leukemia: real-world data. Eur J Haematol 105:3–15. https://doi.org/10.1111/ejh.13408

Article  CAS  PubMed  Google Scholar 

Quintás-Cardama A, Kantarjian H, Ravandi F et al (2009) Bleeding diathesis in patients with chronic myelogenous leukemia receiving dasatinib therapy. Cancer 115:2482–2490. https://doi.org/10.1002/cncr.24257

Article  CAS  PubMed  Google Scholar 

Nazha A, Romo CG, Kantarjian H et al (2013) The clinical impact of ponatinib on the risk of bleeding in patients with chronic myeloid leukemia. Haematologica 98:e131. https://doi.org/10.3324/haematol.2013.091678

Article  PubMed  PubMed Central  Google Scholar